SYT7

Across TCGA pan-cancer cohorts, SYT7 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SYT7 data layer compared with 19 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SYT7 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated SYT7 expression acts as an unfavorable survival marker, although some lineages such as PDAC and GBM show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where SYT7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	II,III,IV	0.959	0.573	<.001	64	view →
LUAD	OS	Tertile	All	0.770	0.918	.012	4	view →
CCRCC	DFS	Median	All	0.075	1.000	.036	3	view →
HNSC	DFS	Tertile	IV	0.515	0.847	.022	3	view →
GBM	DFS	Quartile	All	0.871	0.690	.024	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SYT7–PDAC (OS)

Open the PDAC breakdown →